Literature DB >> 23494985

Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization.

Kuniaki Ota1, Patrick Quint1, Ming Ruan1, Larry Pederson1, Jennifer J Westendorf2,3, Sundeep Khosla1, Merry Jo Oursler1,3.   

Abstract

Osteoclast-mediated bone resorption precedes osteoblast-mediated bone formation through early adulthood, but formation fails to keep pace with resorption during aging. We previously identified several factors produced by osteoclasts that promote bone formation. In this study, we determined if osteoclast-produced factors contribute to the impaired bone formation with aging. We previously found that mice between the ages of 18 and 22 months develop age-related bone loss. Bone marrow-derived pre-osteoclasts were isolated from 6-week, 12-month, and 18- to 24-month-old mice and differentiated into osteoclasts in vitro. Conditioned media were collected and compared for osteoblast mineralization support. Conditioned medium from osteoclasts from all ages was able to support mineralization of bone marrow stromal cells. Concentrating the conditioned medium from 6-week-old and 12-month-old mouse marrow cells-derived osteoclasts enhanced mineralization support whereas concentrated conditioned medium from 18- to 24-month-old mouse marrow-derived osteoclasts repressed mineralization compared to base medium. This observation suggests that an inhibitor of mineralization was secreted by aged murine osteoclasts. Gene and protein analysis revealed that the Wnt antagonist sclerostin was significantly elevated in the conditioned media from 24-month-old mouse cells compared to 6-week-old mouse cells. Antibodies directed to sclerostin neutralized the influences of the aged mouse cell concentrated conditioned media on mineralization. Sclerostin is primarily produced by osteocytes in young animals. This study demonstrates that osteoclasts from aged mice also produce sclerostin in quantities that may contribute to the age-related impairment in bone formation.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23494985      PMCID: PMC3895454          DOI: 10.1002/jcb.24537

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  43 in total

1.  Osteoclasts: what do they do and how do they do it?

Authors:  Steven L Teitelbaum
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

2.  Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

Authors:  Gabriela G Loots; Michaela Kneissel; Hansjoerg Keller; Myma Baptist; Jessie Chang; Nicole M Collette; Dmitriy Ovcharenko; Ingrid Plajzer-Frick; Edward M Rubin
Journal:  Genome Res       Date:  2005-06-17       Impact factor: 9.043

Review 3.  Molecular mechanisms in coupling of bone formation to resorption.

Authors:  T Martin; Jonathan H Gooi; Natalie A Sims
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

4.  Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism.

Authors:  Ayyakannu Ayyanan; Gianluca Civenni; Laura Ciarloni; Catherine Morel; Nathalie Mueller; Karine Lefort; Anna Mandinova; Wassim Raffoul; Maryse Fiche; Gian Paolo Dotto; Cathrin Brisken
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-24       Impact factor: 11.205

5.  SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.

Authors:  Mikhail Semënov; Keiko Tamai; Xi He
Journal:  J Biol Chem       Date:  2005-05-20       Impact factor: 5.157

6.  Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate.

Authors:  Larry Pederson; Ming Ruan; Jennifer J Westendorf; Sundeep Khosla; Merry Jo Oursler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

Review 7.  Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer.

Authors:  Sarah J Zardawi; Sandra A O'Toole; Robert L Sutherland; Elizabeth A Musgrove
Journal:  Histol Histopathol       Date:  2009-03       Impact factor: 2.303

8.  Redundant expression of canonical Wnt ligands in human breast cancer cell lines.

Authors:  Khemais Benhaj; Kamil Can Akcali; Mehmet Ozturk
Journal:  Oncol Rep       Date:  2006-03       Impact factor: 3.906

Review 9.  Building bone to reverse osteoporosis and repair fractures.

Authors:  Sundeep Khosla; Jennifer J Westendorf; Merry Jo Oursler
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

10.  Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Authors:  Xiaodong Li; Michael S Ominsky; Qing-Tian Niu; Ning Sun; Betsy Daugherty; Diane D'Agostin; Carole Kurahara; Yongming Gao; Jin Cao; Jianhua Gong; Frank Asuncion; Mauricio Barrero; Kelly Warmington; Denise Dwyer; Marina Stolina; Sean Morony; Ildiko Sarosi; Paul J Kostenuik; David L Lacey; W Scott Simonet; Hua Zhu Ke; Chris Paszty
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

View more
  30 in total

1.  Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women.

Authors:  Koji Fujita; Matthew M Roforth; Susan Demaray; Ulrike McGregor; Salman Kirmani; Louise K McCready; James M Peterson; Matthew T Drake; David G Monroe; Sundeep Khosla
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

Review 2.  Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.

Authors:  Michelle M McDonald; Jesus Delgado-Calle
Journal:  Curr Osteoporos Rep       Date:  2017-12       Impact factor: 5.096

3.  Mechanisms of osteoclast-dependent bone formation.

Authors:  Anna Teti
Journal:  Bonekey Rep       Date:  2013-12-04

Review 4.  Role and mechanism of action of sclerostin in bone.

Authors:  Jesus Delgado-Calle; Amy Y Sato; Teresita Bellido
Journal:  Bone       Date:  2016-10-12       Impact factor: 4.398

Review 5.  Sclerostin expression and functions beyond the osteocyte.

Authors:  Megan M Weivoda; Stephanie J Youssef; Merry Jo Oursler
Journal:  Bone       Date:  2016-11-23       Impact factor: 4.398

Review 6.  Osteoblast-osteoclast interactions.

Authors:  Xiao Chen; Zhongqiu Wang; Na Duan; Guoying Zhu; Edward M Schwarz; Chao Xie
Journal:  Connect Tissue Res       Date:  2017-03-21       Impact factor: 3.417

Review 7.  Osteocytes: master orchestrators of bone.

Authors:  Mitchell B Schaffler; Wing-Yee Cheung; Robert Majeska; Oran Kennedy
Journal:  Calcif Tissue Int       Date:  2013-09-17       Impact factor: 4.333

Review 8.  Osteoclasts: more than 'bone eaters'.

Authors:  Julia F Charles; Antonios O Aliprantis
Journal:  Trends Mol Med       Date:  2014-07-06       Impact factor: 11.951

Review 9.  Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.

Authors:  Megan M Weivoda; Merry Jo Oursler
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

10.  Associations of serum sclerostin with bone mineral density, markers of bone metabolism and thalassaemia characteristics in adult patients with transfusion-dependent beta-thalassaemia.

Authors:  Katya Sapunarova; Vesselina Goranova-Marinova; Pencho Georgiev; Tanya Deneva; Silvia Tsvetkova; Zhanet Grudeva-Popova
Journal:  Ann Med       Date:  2020-03-26       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.